NASDAQ: MIRAMira Pharmaceuticals Inc Stock
$0.82-0.03 (-3.53%)
Updated May 1, 2024
MIRA Price
$0.82
Fair Value Price
$0.25
Market Cap
$12.11M
52 Week Low
$0.76
52 Week High
$7.98
P/E
-1.28x
P/B
2.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$5M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MIRA Overview
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MIRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIRA ($0.82) is overvalued by 230.74% relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MIRA ($0.82) is not significantly undervalued (230.74%) relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MIRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MIRA due diligence checks available for Premium users.
Be the first to know about important MIRA news, forecast changes, insider trades & much more!
MIRA News
Valuation
MIRA fair value
Fair Value of MIRA stock based on Discounted Cash Flow (DCF)
Price
$0.82
Fair Value
$0.25
Overvalued by
231.14%
MIRA ($0.82) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MIRA ($0.82) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MIRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MIRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.28x
Industry
7.71x
Market
37.67x
MIRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
6.02x
MIRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.8M
Profit Margin
0%
MIRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.9M
Liabilities
$558.1k
Debt to equity
0.13
MIRA's short-term assets ($4.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIRA's short-term assets ($4.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$0.0
Financing
-$230.7k
MIRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MIRA vs Biotech Stocks
Mira Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.